AMENDMENT TRANSMITTAL LETTER (Large Entity) Applicant(s): Ingold et al.					Docket No. PU4722USW	
Application No. 10/505,337	Filing Date 8/23/04	Examiner Yong Chu	Customer 23347	No.	Group Art Unit 1626	Confirmation No.
Invention: PROCESS FOR PREPARATION OF SUBSTITUTED OXAZOLES/THIAZOLES (as amended)						
COMMISSIONER FOR PATENTS:  Transmitted herewith is an amendment in the above-identified application.  The fee has been calculated and is transmitted as shown below.						
CLAIMS AS AMENDED						
	CLAIMS REMAINING	HIGHEST#	NUMBER EXTRA		RATE	ADDITIONAL FEE
TOTAL CLAIMS	23 -	23 =	0	x	\$50.00	\$0.00
INDEP, CLAIMS	4 -	4 =	0	×	\$200.00	\$0.00
Multiple Dependent Claims (check if applicable)						\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT \$0.00						
<ul> <li>□ Please charge Deposit Account No. in the amount of</li> <li>□ A check in the amount of to cover the filing fee is enclosed.</li> <li>☑ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 07-1392</li> <li>☑ Any additional filing fees required under 37 C.F.R. 1.16.</li> <li>☑ Any patent application processing fees under 37 CFR 1.17.</li> <li>□ Payment by credit card. Form PTO-2038.</li> <li>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</li> </ul>						
Attorney for App GlaxoSmithKline Five Moore Drive	: e, PO Box 13398 le Park, NC 27709-3398   483-8247		the United States class mail in an env P.O. Box 1450, Alex (Date)	Posta elope candri	I Service with sue addressed to "Coa, VA 22313-1450	

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ingold, et al

Serial No.:

10/505,337

Examiner: Yong Chu

Filing Date:

August 23, 2004

Art Unit: 1626

PROCESS FOR PREPARATION OF SUBSTITUTED

OXAZOLES/THIAZOLES (as amended)

**Commissioner for Patents** Washington D.C. 20231

## SUPPLEMENTAL AMENDMENT

Sir:

This paper is submitted supplemental to the response filed February 8. 2006. Entry of this supplemental amendment and allowance of the application is earnestly solicited. For the purposes of adding the priority information, amending the title and abstract, please amend the application as follows:

Amendments to the Specification begin on page 2.

Remarks/Arguments begin on page 3.

Abstract begins on page 4. Please substitute the attached Abstract, which has been placed on a separate sheet of paper according to US practice.